

Remarks

Claims 82, 89-90, and 93-94 have been amended to include sequence identifiers.

It is respectfully believed that this application complies with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Attn: Helene C. Carlson

Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: 2/7/03

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Version with markings to show changes made

In the Claims:

Claim 82 was amended as follows.

82. (Once amended) The pharmaceutical composition of claim 81, wherein the epitope consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 89 was amended as follows.

89. (Once amended) The diagnostic agent of claim 88, wherein the peptide consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 90 was amended as follows.

90. (Once amended) An isolated cytolytic T cell line which specifically recognizes a complex of an HLA-A3 molecule and a peptide epitope of about 11 amino acids having the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 93 was amended as follows.

93. (Once amended) The isolated antigenic HLA-A3 binding peptide of claim 92 consisting of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Claim 94 was amended as follows.

94. (Once amended) An isolated nucleic acid molecule consisting of a nucleotide sequence encoding the amino acid sequence TTLFCASDAK (SEQ ID NO:32).